Key facts
- Notable investors include Nvidia, Bundesministerium für Wirtschaft und Klimaschutz, Ascenion, Aescuvest, BIH Digital Health Accelerator.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for LIMAA Technologies
- ·The full record, as it builds
Funding rounds
No funding rounds for LIMAA Technologies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About LIMAA Technologies
Developer of an automated tissue-preserving 3D histopathology platform designed to help pathologists increase their sample throughput from tissue preparation to analysis. The company's platform allows clients to analyze entire tissue biospecimens without embedding or slicing and visualization of tissue samples including downstream genomic analysis, enabling pathologists to evaluate guideline-specific multiplexed biomarker staining of tissue samples with cellular 3D spatial resolution in a clinically feasible time.
- Sector
- Healthcare
- HQ
- Berlin, Germany
- Employees
- 6
- Website
- limaa-technologies.com/
- Ownership
- Privately Held (backing)
LIMAA Technologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in LIMAA Technologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on LIMAA Technologies in its N-PORT filings yet. We sweep new filings monthly.